<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331198</url>
  </required_header>
  <id_info>
    <org_study_id>017004</org_study_id>
    <secondary_id>TRANSCEND-CLL-004</secondary_id>
    <nct_id>NCT03331198</nct_id>
  </id_info>
  <brief_title>Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)</brief_title>
  <official_title>An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juno Therapeutics, a Subsidiary of Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Juno Therapeutics, a Subsidiary of Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of&#xD;
      JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a&#xD;
      Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with&#xD;
      relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy&#xD;
      and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1&#xD;
      cohort will assess the combination of JCAR017 and concurrent ibrutinib. Another separate&#xD;
      Phase 1 cohort will assess the combination of JCAR017 and concurrent venetoclax. In all&#xD;
      subjects, the safety, efficacy, and pharmacokinetics (PK) of JCAR017 will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 26, 2017</start_date>
  <completion_date type="Anticipated">December 4, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 1: subjects will be assigned to receive JCAR017, or JCAR017 + ibrutinib Phase 2: subjects will be assigned to receive JCAR017 at the recommended dose</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 JCAR017 and ibrutinib combination dose escalation therapy arm: adverse events</measure>
    <time_frame>Through post treatment Day 90</time_frame>
    <description>Proportion of subjects experiencing adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 JCAR017 and ibrutinib combination dose escalation therapy arm: laboratory abnormalities</measure>
    <time_frame>Through post treatment Day 90</time_frame>
    <description>Proportion of subjects experiencing laboratory abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm</measure>
    <time_frame>Through post treatment up to Month 48</time_frame>
    <description>Proportion of subjects who have CR after treatment with JCAR017 + ibrutinib using iwCLL 2018 guidelines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm</measure>
    <time_frame>Through post treatment Day 90</time_frame>
    <description>Recommended dose of venetoclax in combination with JCAR017 based on assessment of data from each dose level of venetoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: adverse events</measure>
    <time_frame>Through post treatment Day 90</time_frame>
    <description>Proportion of subjects experiencing adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: laboratory abnormalities</measure>
    <time_frame>Through post treatment Day 90</time_frame>
    <description>Proportion of subjects experiencing laboratory abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm</measure>
    <time_frame>Through post treatment up to Month 48</time_frame>
    <description>Proportion of subjects who have CR after treatment with JCAR017 + venetoclax using iwCLL 2018 guidelines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: ORR</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Defined as the rate of CR (including CRi)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: adverse events</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Proportion of subjects experiencing adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: laboratory abnormalities</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Proportion of subjects experiencing laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: MRD negative response rate in peripheral blood</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Proportion of subjects who achieve MRD CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: MRD-negative CR rate in peripheral blood</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Proportion of subjects who achieve MRD CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: Duration of response (DOR)</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Defined as the time from first response (CR, CRi, nPR, or PR) to the earlier date of PD or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: Duration of complete response (DoCR)</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Defined as the time from first CR or CRi to the earlier date of PD or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: Time to response (TTR)</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Defined as the interval from JCAR017 infusion to the first documentation of CR, CRi, nPR, or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: PFS</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Defined as the time from JCAR017 infusion to the earlier date of PD or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: OS</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Defined as the time from JCAR017 infusion to the date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: Time to complete response (TTCR)</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Defined as the interval from JCAR017 infusion to the first documentation of CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: ORR</measure>
    <time_frame>Through post treatment Day 90</time_frame>
    <description>Defined as the rate of CR (including CRi)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: adverse events</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Proportion of subject experiencing adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: lab abnormalities</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Proportion of subjects experiencing laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: MRD-negative response rate in peripheral blood</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Proportion of subjects who achieve MRD CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: MRD-negative CR rate in peripheral blood</measure>
    <time_frame>Through post treatment Day 90</time_frame>
    <description>Proportion of subjects who achieve MRD CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: Duration of response (DOR)</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Defined as the time from first response (CR, CRi, nPR, or PR) to the earlier date of PD or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: Duration of complete response (DoCR)</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Defined as the time from first CR or CRi to the earlier date of PD or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: Time to response (TTR)</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Defined as the interval from JCAR017 infusion to the first documentation of CR, CRi, nPR, or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: Time to complete response (TTCR)</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Defined as the interval from JCAR017 infusion to the first documentation of CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: PFS</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Defined as the time from JCAR017 infusion to the earlier date of PD or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm: OS</measure>
    <time_frame>Up to 48 months post treatment</time_frame>
    <description>Defined as the time from JCAR017 infusion to the date of death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Leukemia, Lymphocytic, Chronic, B-Cell</condition>
  <condition>Lymphoma, Small Lymphocytic</condition>
  <arm_group>
    <arm_group_label>Phase 1 JCAR017 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be assigned to receive JCAR017 (lisocabtagene maraleucel)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 JCAR017 + ibrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving ibrutinib at baseline will be assigned to receive JCAR017 (lisocabtagene maraleucel) at the recommended dose + ibrutinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 JCAR017 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 JCAR017 + venetoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive venetoclax as bridging anticancer therapy until lymphodepletion chemotherapy/ JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm. After JCAR017 infusion subjects will receive venetoclax until Day 90.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JCAR017 (lisocabtagene maraleucel)</intervention_name>
    <description>Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants will receive venetoclax as bridging anticancer therapy on a weekly ramp up dosing schedule until stopping one day prior to lymphodepletion. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection, and the day after infusion venetoclax will be re-initiated.</description>
    <arm_group_label>Phase 1 JCAR017 + venetoclax</arm_group_label>
    <arm_group_label>Phase 1 JCAR017 monotherapy</arm_group_label>
    <arm_group_label>Phase 2 JCAR017 monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JCAR017 (lisocabtagene maraleucel) + ibrutinib</intervention_name>
    <description>Participants eligible for this cohort should be receiving ibrutinib at the time of screening. For participants who previously discontinued ibrutinib, ibrutinib will be started as soon as possible after eligibility is confirmed. Ibrutinib treatment will continue for up to 90 days after JCAR017 infusion (or longer for participants who are receiving benefit from ibrutinib). Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.</description>
    <arm_group_label>Phase 1 JCAR017 + ibrutinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JCAR017 (lisocabtagene maraleucel) + venetoclax</intervention_name>
    <description>Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants will receive venetoclax as bridging anticancer therapy on a weekly ramp up dosing schedule until stopping one day prior to lymphodepletion. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection, and the day after infusion venetoclax will be re-initiated.</description>
    <arm_group_label>Phase 1 JCAR017 + venetoclax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of:&#xD;
&#xD;
               1. CLL with an indication for treatment based on the Investigator's opinion and&#xD;
                  measurable disease, or&#xD;
&#xD;
               2. SLL (lymphadenopathy and/or splenomegaly and &lt; 5×10^9 CD19+ CD5+ clonal B&#xD;
                  lymphocytes/L [&lt; 5000/µL] in the peripheral blood at diagnosis with measurable&#xD;
                  disease that is biopsy-proven SLL)&#xD;
&#xD;
          -  Subjects (other than those in the ibrutinib + JCAR017 combination therapy cohort) must&#xD;
             have received and failed Bruton tyrosine kinase inhibitor (BTKi) treatment or have&#xD;
             been deemed ineligible for BTKi therapy.&#xD;
&#xD;
          -  Subjects (other than those in the ibrutinib + JCAR017 combination therapy cohort) must&#xD;
             have received previous treatment as follows:&#xD;
&#xD;
               1. Subjects with CLL or SLL and high-risk features must have failed at least 2 lines&#xD;
                  of prior therapy.&#xD;
&#xD;
               2. Subjects with CLL or SLL and standard-risk features must have failed at least 3&#xD;
                  lines of prior therapy.&#xD;
&#xD;
          -  Subjects in the ibrutinib + JCAR017 combination therapy cohort must either:&#xD;
&#xD;
               1. be receiving ibrutinib and progressing at the time of study enrollment&#xD;
&#xD;
               2. be receiving ibrutinib for at least 6 months with a response less than complete&#xD;
                  response/remission (CR) and have high-risk features as defined in inclusion&#xD;
                  criterion 5a&#xD;
&#xD;
               3. have BTK or PLCgamma2 mutations per local laboratory assessment, with or without&#xD;
                  progression on ibrutinib&#xD;
&#xD;
               4. have previously received ibrutinib and have no contraindications to restarting&#xD;
                  ibrutinib&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status of ≤ 1&#xD;
&#xD;
          -  Assessed by the Investigator to have adequate bone marrow function to receive&#xD;
             lymphodepleting chemotherapy&#xD;
&#xD;
          -  Adequate organ function, defined as:&#xD;
&#xD;
               1. Serum creatinine ≤ 1.5 × age-adjusted upper limit of normal (ULN) OR calculated&#xD;
                  creatinine clearance &gt; 30 mL/min&#xD;
&#xD;
               2. Alanine aminotransferase ≤ 5 × ULN and total bilirubin &lt; 2.0 mg/dL (or &lt; 3.0&#xD;
                  mg/dL for subjects with Gilbert's syndrome or leukemic infiltration of the liver)&#xD;
&#xD;
               3. Adequate pulmonary function, defined as ≤ Common Terminology Criteria for Adverse&#xD;
                  Events (CTCAE) Grade 1 dyspnea and saturated oxygen (SaO2) ≥ 92% on room air&#xD;
&#xD;
               4. Adequate cardiac function, defined as left ventricular ejection fraction ≥ 40% as&#xD;
                  assessed by echocardiogram or multiple uptake gated acquisition scan performed&#xD;
                  within 30 days prior to determination of eligibility&#xD;
&#xD;
          -  Subject either currently has central vascular access or is a candidate to receive&#xD;
             central vascular access or peripheral vascular access for leukapheresis procedure.&#xD;
&#xD;
          -  If prior CD19-targeted therapy has been administered, subject must have CD19-positive&#xD;
             disease confirmed by immunohistochemistry or flow cytometry since completing the prior&#xD;
             CD19-targeted therapy.&#xD;
&#xD;
          -  Subjects in ibrutinib + JCAR017 combination cohort must have progressed on a BTKi and&#xD;
             have received prior therapy with venetoclax&#xD;
&#xD;
          -  Subjects in venetoclax + JCAR017 combination cohort must:&#xD;
&#xD;
               1. have failed at least 1 prior line of therapy, including failed BTKi therapy or&#xD;
                  have been deemed ineligible to receive BTKi&#xD;
&#xD;
               2. be venetoclax naive (required for dose expansion) or&#xD;
&#xD;
               3. if prior venetoclax (only for dose escalation)&#xD;
&#xD;
               4. have no contraindictions to re-initiation of venetoclax based on prior&#xD;
                  intolerance and have had at least 6 months elapsed since the last dose of&#xD;
                  venetoclax, if either, best response was stable disease, or subject experienced&#xD;
                  disease progression on venetoclax, or within 6 months of venetoclax&#xD;
                  discontinuation&#xD;
&#xD;
          -  subjects in the venetoclax + JCAR017 combination must have hemoglobin &gt;=9 g/dL,&#xD;
             absolute neutrophil count &gt;=500mm3 and platelets&gt;= 75,000/mm3, unless cytopenias are&#xD;
             judged by investigator to be due to CLL infiltration of the bone marrow&#xD;
&#xD;
          -  must have diagnosis of CLL or SLL with an indication for treatment based on the&#xD;
             investigator's opinion and measurable disease (any of the following measurable lymph&#xD;
             nodes ≥1.5 cm in the greatest transverse diameter and/or hepatomegaly or splenomegaly)&#xD;
             and demonstration of CLL cells in the peripheral blood by flow cytometry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with known active central nervous system (CNS) involvement by malignancy.&#xD;
             Those with prior CNS disease that has been effectively treated will be eligible if&#xD;
             treatment was completed at least 3 months prior to enrollment with no evidence of&#xD;
             symptomatic disease and stable abnormalities on repeat imaging.&#xD;
&#xD;
          -  History of another primary malignancy that has not been in remission for at least 2&#xD;
             years. (The following are exempt from the 2-year limit: nonmelanoma skin cancer,&#xD;
             completely resected stage 1 solid tumor with low risk for recurrence, curatively&#xD;
             treated localized prostate cancer, cervical carcinoma in situ on biopsy or a squamous&#xD;
             intraepithelial lesion on Pap smear, and in situ breast cancer that has been&#xD;
             completely resected.)&#xD;
&#xD;
          -  Subjects with Richter's transformation&#xD;
&#xD;
          -  Prior treatment with any gene therapy product&#xD;
&#xD;
          -  Active hepatitis B, active hepatitis C, or active human immunodeficiency virus (HIV)&#xD;
             infection&#xD;
&#xD;
          -  Systemic fungal, bacterial, viral, or other infection that is not controlled&#xD;
&#xD;
          -  Presence of acute or extensive chronic graft versus host disease (GVHD)&#xD;
&#xD;
          -  History of any one of the following cardiovascular conditions within the past 6&#xD;
             months: Class III or IV heart failure as defined by the New York Heart Association&#xD;
             (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or&#xD;
             other clinically significant cardiac disease&#xD;
&#xD;
          -  History or presence of clinically relevant CNS pathology such as epilepsy, generalized&#xD;
             seizure disorder, aphasia, stroke with current neurologic sequelae, severe brain&#xD;
             injuries, dementia, Parkinson's disease, cerebellar disease,cerebral edema, or&#xD;
             psychosis&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  Use of any of the following medications or treatments within the noted time prior to&#xD;
             leukapheresis:&#xD;
&#xD;
               1. Alemtuzumab within 6 months prior to leukapheresis&#xD;
&#xD;
               2. Allogeneic hematopoietic stem cell transplant within 100 days prior to&#xD;
                  leukapheresis&#xD;
&#xD;
               3. Cladribine within 3 months prior to leukapheresis&#xD;
&#xD;
               4. Donor lymphocyte infusions (DLI) within 2 months prior to leukapheresis&#xD;
&#xD;
               5. Radiation including large bone marrow fields such as sternum or pelvis within 6&#xD;
                  weeks prior to leukapheresis&#xD;
&#xD;
               6. Fludarabine within 4 weeks prior to leukapheresis&#xD;
&#xD;
               7. GVHD therapies such as calcineurin inhibitors, methotrexate or other&#xD;
                  chemotherapeutics, mycophenolate mofetil, rapamycin, or immunosuppressive&#xD;
                  antibodies (such as anti-tumor necrosis factor-α [TNFα], anti-interleukin-6&#xD;
                  [IL-6], or anti-interleukin-6 receptor [IL 6R]) within 4 weeks prior to&#xD;
                  leukapheresis&#xD;
&#xD;
               8. Cyclophosphamide, ifosfamide, bendamustine, chlorambucil, or melphalan within 2&#xD;
                  weeks prior to leukapheresis&#xD;
&#xD;
               9. Therapeutic doses of corticosteroids (defined as &gt; 20 mg/day prednisone or&#xD;
                  equivalent) within 7 days prior to leukapheresis&#xD;
&#xD;
              10. Anti-CD20 monoclonal antibodies within 7 days prior to leukapheresis&#xD;
&#xD;
              11. Venetoclax within 4 days prior to leukapheresis&#xD;
&#xD;
              12. Idelalisib or duvelisib within 2 days prior to leukapheresis&#xD;
&#xD;
              13. Lenalidomide within 1 day prior to leukapheresis&#xD;
&#xD;
              14. Experimental agents, including off-label use of approved drugs (with the&#xD;
                  exception of acalabrutinib which may be continued up to the day before&#xD;
                  leukapheresis), within 4 weeks prior to leukapheresis unless progression is&#xD;
                  documented on the experimental therapy and at least 3 half-lives have elapsed&#xD;
                  prior to leukapheresis&#xD;
&#xD;
          -  Uncontrolled medical, psychological, familial, sociological, or geographical&#xD;
             conditions that do not permit compliance with the protocol, as judged by the&#xD;
             Investigator; or subject unwillingness or inability to follow the procedures required&#xD;
             in the protocol&#xD;
&#xD;
          -  Progressive vascular tumor invasion, thrombosis, or embolism&#xD;
&#xD;
          -  Deep vein thrombosis or embolism not managed on a stable regimen of anticoagulation&#xD;
&#xD;
          -  Use of any of the following medications or treatments within the noted time prior to&#xD;
             leukapheresis lenalidomide or acalabrutinib within 1 day prior to leukapheresis&#xD;
             experimental agents, including off-label use of approved drugs, within 4 weeks prior&#xD;
             to leukapheresis.&#xD;
&#xD;
          -  Venous thrombosis or embolism requiring treatment but not managed on a stable regimen&#xD;
             of anticoagulation&#xD;
&#xD;
          -  For subjects in the venetoclax + JCAR017 combination cohorts only, concomitant&#xD;
             treatment with CYP3A moderate/strong inducers or moderate/strong inhibitors which&#xD;
             cannot be discontinued&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heidi Gillenwater, MD</last_name>
    <role>Study Director</role>
    <affiliation>Juno Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Hill</last_name>
      <phone>205-996-8023</phone>
      <email>tiffanydhill@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Danielle Mussey</last_name>
      <phone>205-996-1795</phone>
      <email>dmussey@uabmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Amitkumar Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Noggy</last_name>
      <phone>480-256-3425</phone>
      <email>brenda.noggy@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Rajneesh Nath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hormoz Mirshkarlo, MD</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>69074</phone_ext>
      <email>hmirshkarlo@coh.org</email>
    </contact>
    <investigator>
      <last_name>Tanya Siddiqi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krisma C Montalvo</last_name>
      <phone>858-246-0386</phone>
      <email>kcmontalvo@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Aguilar</last_name>
      <phone>858-534-5201</phone>
      <email>k1aguilar@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas J Kipps, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Valadez</last_name>
      <phone>310-794-6500</phone>
      <email>jvaladez@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anna Crosetti</last_name>
      <phone>310-794-6500</phone>
      <email>acrosetti@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Herbert Eradat, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Chon</last_name>
      <phone>415-476-2351</phone>
      <email>andrew.chon@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Lawrence Kaplan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pari Ramzi</last_name>
      <phone>202-784-0038</phone>
      <email>ramzip1@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Pashna Munshi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Kharfan-Dabaja, MD</last_name>
      <phone>904-953-2000</phone>
      <email>kharfandabaja.mohamed@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Teresa Banda</last_name>
      <phone>214-820-1660</phone>
      <email>teresa.banda@bswhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mohamed Kharfan-Dabaja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Blood and Marrow Transplant Group of Georgia (BMTGA)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott R Solomon, MD</last_name>
      <phone>404-255-1930</phone>
      <email>ssolomon@bmtga.com</email>
    </contact>
    <contact_backup>
      <last_name>Stacey Brown</last_name>
      <phone>404-780-7965</phone>
      <email>Stacey.brown@northside.com</email>
    </contact_backup>
    <investigator>
      <last_name>Scott R Solomon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-695-1301</phone>
      <email>cancertrials@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Arezou Ireta</last_name>
      <phone>312-695-8169</phone>
      <email>a-ireta@northwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Shuo Ma, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sadi Dixon, RN</last_name>
      <phone>773-702-2070</phone>
      <email>sdixon2@medicine.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elaine Hoekstra</last_name>
      <phone>773-884-8528</phone>
      <email>ehoekstra1@medicine.bsd.uchicago.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Riedell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob D Soumerai, MD</last_name>
      <phone>617-724-4000</phone>
      <email>jsoumerai@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Jacob D Soumerai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Logan, RN</last_name>
      <phone>617-667-5984</phone>
      <email>eklogan@bidmc.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pavania Elavalakanar</last_name>
      <phone>617-667-1903</phone>
      <email>pelavala@bidmc.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jon Arnason, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5362</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>U of M Cancer Answerline</last_name>
      <phone>800-865-1125</phone>
    </contact>
    <investigator>
      <last_name>Monalisa Ghosh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo En Kim, MPH</last_name>
      <phone>313-576-8030</phone>
      <email>kimjo@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Abhinav Deol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <contact_backup>
      <last_name>Gabrielle Bouska</last_name>
      <phone>507-538-0586</phone>
      <email>bouska.gabrielle@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Saad Kenderian, MB, ChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail A Paulsen</last_name>
      <phone>402-559-3853</phone>
      <email>gpaulsen@unmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lindsay Hicks</last_name>
      <phone>402-559-6044</phone>
      <email>lindsay.hick@unmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Julie Vose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Yannotti, RNC</last_name>
      <phone>551-996-5168</phone>
      <email>Kara.Yannotti@Hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Tatyana Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oona Harrigan</last_name>
      <phone>732-235-5609</phone>
      <email>oh77@cinj.rutgers.edu</email>
    </contact>
    <contact_backup>
      <last_name>Roger Strair, MD, PhD</last_name>
      <phone>732-235-4523</phone>
      <email>strairrk@cinj.rutgers.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Roger Strair, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>June Greenburg</last_name>
      <phone>212-746-2651</phone>
      <email>jdg2002@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Koen Van Besien</last_name>
      <phone>212-746-2048</phone>
      <email>kov9001@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Koen Van Besien, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Stowe</last_name>
      <phone>919-681-4769</phone>
      <email>rachel.stowe@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Danielle M Brander, MD</last_name>
      <phone>919-684-8964</phone>
      <email>danielle.brander@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Danielle M Brander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Seidman Cancer Center (Case Western)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Caimi, MD</last_name>
      <phone>216-844-3951</phone>
      <email>Paolo.Caimi@UHhospitals.org</email>
    </contact>
    <contact_backup>
      <last_name>Yeritza Hernandez-Collazo, MS</last_name>
      <phone>216-844-3951</phone>
      <email>Yeritza.Hernandez-Collazo@UHhospitals.org</email>
    </contact_backup>
    <investigator>
      <last_name>Paolo Caimi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center (Stephenson Cancer Center)</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Asch, MD</last_name>
      <phone>405-271-8000</phone>
      <email>adam-asch@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Asch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Perelman Center for Advanced Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Schuster, MD</last_name>
      <phone>215-662-6065</phone>
      <email>stephen.schuster@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Schuster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Scott</last_name>
      <phone>215-955-5903</phone>
      <email>allison.scott@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Carabasi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Fukas</last_name>
    </contact>
    <contact_backup>
      <phone>412-623-6037</phone>
      <email>fukaslj@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kathleen Dorritie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Houston E Holmes III, MD, FACP</last_name>
      <phone>214-370-1077</phone>
    </contact>
    <investigator>
      <last_name>Houston E Holmes III, MD, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Saltarski</last_name>
      <phone>214-648-7030</phone>
      <email>courtney.saltarski@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Farrukh Awan, MD</last_name>
      <phone>214-648-4077</phone>
      <email>farrukh.awan@utsouthwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Farrukh Awan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William G Wierda, MD, PhD</last_name>
      <phone>713-792-7026</phone>
      <email>wwierda@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>William G Wierda, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kolleen Hicks, BS</last_name>
      <phone>801-587-7604</phone>
      <email>Kolleen.Hicks@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Deborah Stephens, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SCCA Immunotherapy Trials Intake</last_name>
      <phone>206-606-4668</phone>
      <email>immunotherapy@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>David Maloney, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nirav Shah, MD</last_name>
      <phone>414-805-4600</phone>
      <email>nishah@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Nirav Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 29, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TRANSCEND_CLL_004</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

